New lung cancer drug challenges standard treatment in major trial
NCT ID NCT05499390
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial compares a new drug, AK112, to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 398 participants with stage IIIB/C or IV cancer will receive either AK112 or pembrolizumab. The main goal is to see if AK112 can delay cancer growth better than pembrolizumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China